{"id":"gadoteric-acid","rwe":[],"tags":[{"label":"gadoteric acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"V08CA02","category":"atc"},{"label":"Active","category":"status"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["gadoteric acid"],"offLabel":[],"synonyms":["gadoteric acid"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"gadoteric acid","explanation":"Imagine you're trying to take a picture of a dark room. Without any light, it's hard to see anything. Gadoteric acid is like a special light that helps the MRI machine see inside the body more clearly, by making the magnetic signals stronger and more visible.","oneSentence":"Gadoteric acid works by altering the magnetic properties of MRI images to enhance contrast.","technicalDetail":"Gadoteric acid is a gadolinium-based contrast agent that works by shortening the T1 relaxation time of protons in the body, allowing for improved visualization of internal structures during MRI."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4559","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GADOTERIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GADOTERIC ACID","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:38:46.538495","biosimilars":[],"competitors":[{"drugName":"gadopentetate dimeglumine","drugSlug":"gadopentetate-dimeglumine","fdaApproval":"1988-06-02","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadodiamide","drugSlug":"gadodiamide","fdaApproval":"1993-01-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadoteridol","drugSlug":"gadoteridol","fdaApproval":"1992-11-16","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mangafodipir","drugSlug":"mangafodipir","fdaApproval":"1997-11-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadoversetamide","drugSlug":"gadoversetamide","fdaApproval":"1999-12-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadobutrol","drugSlug":"gadobutrol","fdaApproval":"2011-03-14","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gadofosveset","drugSlug":"gadofosveset","fdaApproval":"2008-12-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadopiclenol","drugSlug":"gadopiclenol","fdaApproval":"2022-09-21","patentExpiry":"Sep 19, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"gadoteric acid","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"gadopentetate-dimeglumine","brandName":"gadopentetate dimeglumine","genericName":"gadopentetate dimeglumine","approvalYear":"1988","relationship":"same-class"},{"drugId":"gadodiamide","brandName":"gadodiamide","genericName":"gadodiamide","approvalYear":"1993","relationship":"same-class"},{"drugId":"gadoteridol","brandName":"gadoteridol","genericName":"gadoteridol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mangafodipir","brandName":"mangafodipir","genericName":"mangafodipir","approvalYear":"1997","relationship":"same-class"},{"drugId":"gadoversetamide","brandName":"gadoversetamide","genericName":"gadoversetamide","approvalYear":"1999","relationship":"same-class"},{"drugId":"gadobutrol","brandName":"gadobutrol","genericName":"gadobutrol","approvalYear":"2011","relationship":"same-class"},{"drugId":"gadofosveset","brandName":"gadofosveset","genericName":"gadofosveset","approvalYear":"2008","relationship":"same-class"},{"drugId":"gadopiclenol","brandName":"gadopiclenol","genericName":"gadopiclenol","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04657835","phase":"NA","title":"Multiparametric MRI Assessment of Atrial Heart Disease as a Predictor of Atrial Fibrillation After Myocardial Revascularization Surgery","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-05-01","conditions":["Postoperative Atrial Fibrillation"],"enrollment":100,"completionDate":"2028-12"},{"nctId":"NCT06057168","phase":"PHASE3","title":"Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas","status":"COMPLETED","sponsor":"Guerbet","startDate":"2023-09-07","conditions":["Brain Tumor, Primary","Brain Tumor, Recurrent"],"enrollment":138,"completionDate":"2024-11-28"},{"nctId":"NCT07346131","phase":"PHASE4","title":"ELUDYN: Assessment of Intra-individual Variability of Vascular Dynamics of Gadopiclenol Injection Parameters in Contrast-enhanced MRI","status":"RECRUITING","sponsor":"Hôpital Fribourgeois","startDate":"2026-01-07","conditions":["Contrast Agent","Medical Imaging Data","MRI Image Enhancement"],"enrollment":10,"completionDate":"2027-12-31"},{"nctId":"NCT06731738","phase":"PHASE2","title":"Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.","status":"COMPLETED","sponsor":"IC TARGETS AS","startDate":"2024-11-22","conditions":["Heart Failure With Preserved Ejection Fraction (HFPEF)"],"enrollment":44,"completionDate":"2025-11-29"},{"nctId":"NCT05915728","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":["Contrast Enhancement in Magnetic Resonance Imaging","Non-central Nervous System Pathology"],"enrollment":404,"completionDate":"2024-06-01"},{"nctId":"NCT05915702","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":["Contrast Enhancement in Magnetic Resonance Imaging","Central Nervous System Pathology"],"enrollment":303,"completionDate":"2024-05-31"},{"nctId":"NCT06267807","phase":"NA","title":"Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2024-03-27","conditions":["Lymphatic System Disorders Congenital","Lymphatic Diseases","Noonan Syndrome","Lymphatic Disease"],"enrollment":9,"completionDate":"2025-04-01"},{"nctId":"NCT06191731","phase":"NA","title":"Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations","status":"RECRUITING","sponsor":"Centre Hospitalier Régional Metz-Thionville","startDate":"2024-04-12","conditions":["Magnetic Resonance Imaging"],"enrollment":60,"completionDate":"2026-04-12"},{"nctId":"NCT04776187","phase":"PHASE4","title":"Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2021-03-01","conditions":["Nephrogenic Fibrosing Dermopathy"],"enrollment":600,"completionDate":"2021-12-31"},{"nctId":"NCT04652947","phase":"","title":"MR Quality + Diagnostic Performance for CHC Diagnosis - Gadoxetic Acid, Gadoteric Acid and P03277 Comparison","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2016-12-07","conditions":["Hepatocellular Carcinoma"],"enrollment":30,"completionDate":"2017-10-26"},{"nctId":"NCT02529475","phase":"PHASE4","title":"Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2016-02-01","conditions":["Meniere Disease"],"enrollment":25,"completionDate":"2020-09"},{"nctId":"NCT02609919","phase":"","title":"Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2016-01","conditions":["Adverse Reaction to Drug","Allergic Reaction to Contrast Media"],"enrollment":150,"completionDate":"2019-07-19"},{"nctId":"NCT01806740","phase":"PHASE4","title":"DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC","status":"TERMINATED","sponsor":"Guerbet","startDate":"2013-05-09","conditions":["Hepatocellular Carcinoma"],"enrollment":37,"completionDate":"2015-10-12"},{"nctId":"NCT01254552","phase":"PHASE4","title":"Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis","status":"COMPLETED","sponsor":"Guerbet","startDate":"2010-08","conditions":["Type 2 Diabetes Mellitus","Coronary Atherosclerosis"],"enrollment":351,"completionDate":"2016-10"},{"nctId":"NCT03048006","phase":"","title":"Post-marketing Surveillance Study for Evaluation of Dotarem Safety","status":"COMPLETED","sponsor":"Guerbet","startDate":"2011-01","conditions":["Contrast-enhanced MRI With Dotarem"],"enrollment":44456,"completionDate":"2013-12"},{"nctId":"NCT03041298","phase":"","title":"Post Marketing Surveillance Study for Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance Mammography","status":"COMPLETED","sponsor":"Guerbet","startDate":"2011-09","conditions":["MR Mammography With Dotarem"],"enrollment":1537,"completionDate":"2013-12"},{"nctId":"NCT00980681","phase":"PHASE3","title":"Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)","status":"TERMINATED","sponsor":"Guerbet","startDate":"2009-09","conditions":["Renal Disease"],"enrollment":13,"completionDate":"2010-12"},{"nctId":"NCT01449266","phase":"PHASE1","title":"Safety and Dialysability of Dotarem® in Dialysed Patients","status":"COMPLETED","sponsor":"Guerbet","startDate":"2011-11","conditions":["End-stage Renal Failure"],"enrollment":10,"completionDate":"2012-06"},{"nctId":"NCT00650845","phase":"PHASE4","title":"Renal Safety Evaluation After Dotarem®-Enhanced MRI","status":"COMPLETED","sponsor":"Guerbet","startDate":"2008-01","conditions":["Renal Insufficiency"],"enrollment":135,"completionDate":"2011-08"},{"nctId":"NCT00447889","phase":"PHASE4","title":"A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Angiography","status":"COMPLETED","sponsor":"Guerbet","startDate":"2006-03","conditions":["Arterial Occlusive Disease"],"enrollment":0,"completionDate":"2007-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006171","UNII":"QVF9Y6955W","CHEBI":"CHEBI:73732","INN_ID":"6253","UMLSCUI":"C0771795","ChEMBL_ID":"CHEMBL3833326","KEGG_DRUG":"D08007","DRUGBANK_ID":"DB09132","PUBCHEM_CID":"158536","SNOMEDCT_US":"710812003"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":98,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"V08CA02","allCodes":["V08CA02"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","brandName":"GADOTERIC ACID","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gadoteric acid is a small molecule drug of the gadolinium class, used as a contrast agent in magnetic resonance imaging (MRI). Its exact target is unknown, but it is believed to work by enhancing the contrast of MRI images through magnetic properties. The commercial status of gadoteric acid is unclear, and it may be patented or have generic manufacturers. Key safety considerations include the potential for nephrogenic systemic fibrosis in patients with severe kidney disease. Further research is needed to fully understand the pharmacology and safety of this drug.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}